Hemispherx Biopharma (HEB) Reports Evidence Based Potential of Ampligen Against Ebola
Tweet Send to a Friend
Hemispherx Biopharma (NYSE: HEB) reported today a new peer reviewed publication entitled, "The Quest for Effective Ebola Treatment; Ebola VP35 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE